TY - JOUR
T1 - Metabolic and cardiopulmonary effects of detraining after a structured exercise training programme in young PCOS women
AU - Orio, Francesco
AU - Giallauria, Francesco
AU - Palomba, Stefano
AU - Manguso, Francesco
AU - Orio, Marcello
AU - Tafuri, Domenico
AU - Lombardi, Gaetano
AU - Carmina, Enrico
AU - Colao, Annamaria
AU - Vigorito, Carlo
PY - 2008/6
Y1 - 2008/6
N2 - Objective: The aim of the present study was to determine if the favourable cardiopulmonary and metabolic benefits induced by exercise training (ET) programme are maintained after its cessation. Patients: Thirty-two young overweight polycystic ovary syndrome (PCOS) women matched for age and body mass index (BMI) with other 32 PCOS patients was enrolled. The first group [PCOS-T (trained)] underwent 24-week ET programme, whereas the second [PCOS-DT (detrained)] underwent 12-week ET programme followed by 12-week detraining period. Methods: At baseline, after 12- and 24-week follow-up, all PCOS women were studied for their hormonal (ovarian and adrenal androgens), metabolic (glucose and insulin) and lipid profile, and underwent cardiopulmonary exercise test. Results: After the initial 12-week ET programme, both PCOS-T and PCOS-DT groups, without differences between groups, showed a similar significant (P <0.05) improvement in BMI, fasting insulin, areas under curve insulin (AUC INS), glucose and insulin AUC (AUCGLU/INS), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C) and maximal oxygen consumption at cardiopulmonary exercise test (VO 2max). At 24-week follow-up, PCOS-T group showed a significant (P <0.05) improvement in BMI, fasting insulin, AUCINS, AUC GLU/INS, LDL-C, HDL-C and VO2max, in comparison to baseline and 12-week follow-up. At same follow-up visit, the all parameters resulted significantly (P <0.05) worsened in PCOS-DT group in comparison to 12-week follow-up and PCOS-T group. In PCOS-DT group, no parameter assessed at 24-week follow-up was significantly different in comparison with baseline. Conclusion: In young PCOS women, 12-week detraining resulted in a complete loss of the favourable adaptations obtained after ET.
AB - Objective: The aim of the present study was to determine if the favourable cardiopulmonary and metabolic benefits induced by exercise training (ET) programme are maintained after its cessation. Patients: Thirty-two young overweight polycystic ovary syndrome (PCOS) women matched for age and body mass index (BMI) with other 32 PCOS patients was enrolled. The first group [PCOS-T (trained)] underwent 24-week ET programme, whereas the second [PCOS-DT (detrained)] underwent 12-week ET programme followed by 12-week detraining period. Methods: At baseline, after 12- and 24-week follow-up, all PCOS women were studied for their hormonal (ovarian and adrenal androgens), metabolic (glucose and insulin) and lipid profile, and underwent cardiopulmonary exercise test. Results: After the initial 12-week ET programme, both PCOS-T and PCOS-DT groups, without differences between groups, showed a similar significant (P <0.05) improvement in BMI, fasting insulin, areas under curve insulin (AUC INS), glucose and insulin AUC (AUCGLU/INS), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C) and maximal oxygen consumption at cardiopulmonary exercise test (VO 2max). At 24-week follow-up, PCOS-T group showed a significant (P <0.05) improvement in BMI, fasting insulin, AUCINS, AUC GLU/INS, LDL-C, HDL-C and VO2max, in comparison to baseline and 12-week follow-up. At same follow-up visit, the all parameters resulted significantly (P <0.05) worsened in PCOS-DT group in comparison to 12-week follow-up and PCOS-T group. In PCOS-DT group, no parameter assessed at 24-week follow-up was significantly different in comparison with baseline. Conclusion: In young PCOS women, 12-week detraining resulted in a complete loss of the favourable adaptations obtained after ET.
UR - http://www.scopus.com/inward/record.url?scp=43949088844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43949088844&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2265.2007.03117.x
DO - 10.1111/j.1365-2265.2007.03117.x
M3 - Article
C2 - 17980005
AN - SCOPUS:43949088844
VL - 68
SP - 976
EP - 981
JO - Clinical Endocrinology
JF - Clinical Endocrinology
SN - 0300-0664
IS - 6
ER -